Experimental CAR T-Cell therapy targets rare stiff person syndrome
Disease control
Completed
This phase 2 trial is testing a new treatment called KYV-101 for people with stiff person syndrome (SPS) that hasn't improved with standard therapies. The treatment uses a patient's own immune cells, modified to target and attack certain immune cells that may be causing the disea…
Phase: PHASE2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC